The biotechnology research site
In September 2000 Glycart was founded as a spin-off company from the Swiss Federal Institute of Technology in Zürich, Switzerland. Roche acquired the young biotechnology company in the summer of 2005.
The site is located in Schlieren, Switzerland. Roche Glycart AG has a multinational team (95% research scientists), with a thriving, dynamic biotech culture. The team is headed by Pablo Umaña, Ph.D., and comprises research groups in molecular biology, cell engineering, protein engineering, process biochemistry, cell biological assays, histology, preclinical in vivo pharmacology and tumor immunology.
Roche Glycart AG focuses on product development – from scientific concepts and validation to the corresponding studies. Today the compounds studied and developed are boosting Roche’s significant commitment to offering improved cancer medicines.
Roche Glycart AG
CH- 8952 Schlieren
Tel.: +41 44 755 6161
Fax: +41 44 755 6160
Roche Glycart AG’s mission is to be a leader in developing new generations of engineered antibody products with increased efficacy that address unmet clinical needs and to be an antibody engineering power-house within the Roche Group.